Among the patients treated with anti-PD-1 monotherapy, PD-L1 positive HCC, whether in tumor cells or tumor and immune cells combined, seem to respond better than those with negative PD-L1 expression [12,13,58]. Here, CD274 is linked to hepatocellular carcinoma.